No Data
No Data
Boji Pharmaceuticals (300404): Order growth is impressive, waiting for profit margins to improve
Incident: The company released its 2023 annual report and 2024 quarterly report, of which: 1) In 2023, the company achieved operating income of 556 million yuan (YOY +31.19%); realized net profit of 24 million yuan to mother
The CRO concept was active at the beginning of the market. Baihua Pharmaceutical rose more than 8%, Boji Pharmaceutical rose 7%, and Shuangcheng Pharmaceutical, Haofan Biotech, and Yaben Chemical followed suit.
The CRO concept was active at the beginning of the market. Baihua Pharmaceutical rose more than 8%, Boji Pharmaceutical rose 7%, and Shuangcheng Pharmaceutical, Haofan Biotech, and Yaben Chemical followed suit.
A-share diet drug concept stocks generally rose and Changshan Pharmaceutical rose and stopped
Gelonghui April 25 | Changshan Pharmaceutical rose and stopped by 20cm, while Boji Pharmaceutical, Hanyu Pharmaceutical, Baihua Pharmaceutical, Watson Pharmaceutical, and Borui Pharmaceutical followed suit.
Boji Pharmaceutical (300404.SZ): 2023 net profit of 243.39 million yuan fell 12.04% year on year
On April 24, Ge Longhui Pharmaceutical (300404.SZ) released its 2023 annual report. Operating revenue was 556 million yuan, up 31.19% year on year, net profit of 243.39 million yuan, down 12.04% year on year. After deducting non-net profit of 1.0017 million yuan, a year-on-year decrease of 24.24%, with basic earnings per share of 0.0657 yuan. A cash dividend of 0.1 yuan is distributed to all shareholders for every 10 shares.
Boji Pharmaceutical (300404.SZ): There are no pertussis-related projects
Gelonghui, April 10 | Boji Pharmaceutical (300404.SZ) said on the investor interactive platform that the company has no projects related to pertussis disease yet, but currently provides pre-clinical and clinical research services for various respiratory infection projects.
Boji Pharmaceutical (300404.SZ): There are plans to establish subsidiaries abroad to expand clinical business abroad
Gelonghui, April 10 | Boji Pharmaceutical (300404.SZ) said on the investor interactive platform that the company has set up subsidiaries abroad and plans to expand clinical business abroad, but currently the company's main business is still domestic, and more than 99% of the company's revenue comes from domestic sources. The company is a professional CRO service provider. The service projects cover various pharmaceutical categories such as chemicals, biopharmaceuticals, traditional Chinese medicine, etc., as well as medical devices. Traditional Chinese medicine research and development services are the company's characteristic business area, and the proportion of traditional Chinese medicine business revenue in the first half of 2023 was 20.15% of total revenue.
No Data